Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a novel topical BRAF inhibitor gel called LUT014 ...

LUT014 works by paradoxically reactivating MAPK, a key signaling pathway in the skin that anti-EGFR therapies shut down.

Preclinical data demonstrates synergy of QTX3544 with EGFR inhibitors, broadly enhancing anti-tumor activity - - Data supports ongoing Phase 1 clinical trial for QTX3544 as monotherapy and in ...

Cetuximab therapy was started on the day radiation therapy began with a loading dose of 400 mg/m 2 in the first week, and then 250 mg/m 2 /week for the successive radiation weeks. One cycle of ...

Indeed, results from the FLEX trial demonstrate that cetuximab in combination with platinum-based chemotherapy is a new treatment strategy for patients with advanced NSCLC. The EGFR pathway has an ...

Cetuximab is a monoclonal antibody with activity against colorectal cancers that overexpress epidermal growth factor receptor. This agent blocks epidermal growth factor receptor signaling and ...

NT219, a novel dual inhibitor of IRS1/2 and STAT3, is being evaluated in a Phase 2 study in patients with recurrent and/or metastatic head and neck squamous cell cancer (R/M HNSCC) in combination with ...

Researchers from the UCLA Health Jonsson Comprehensive Cancer Center and The University of Texas MD Anderson Cancer Center have demonstrated that a ...

A doctor given 18 months to live in 2015 has celebrated the decade since her devastating cancer diagnosis by ticking off a bucket list and says "every day is precious". Ten years ago, Mari Isdale, ...

The INTERLINK-1 trial was testing monalizumab – an NKG2A receptor inhibitor – in combination with EGFR-targeting antibody cetuximab in patients with recurrent or metastatic squamous cell ...

The poster will include clinical data as of an April 4, 2025 data cutoff from the Company's ongoing Phase 1/2 clinical trial evaluating azenosertib in combination with encorafenib and cetuximab in ...